Saturday 17 October 2026 Export COR’s income statement to Excel — free account

Cencora, Inc.

Cencora, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $321.3 billion, up 9.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS grew 11.3%, free cash flow grew 3,385.3% and total debt rose 42.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years, revenue growth for ten; insiders bought in the last twelve months.

340.66 0.75 −0.22%

Follow COR

Alert me

Market cap: $65.2B
P/E: 25.2×
Fwd P/E: 14.5×
Dividend yield: 0.70%
F-score: 6/9
Altman Z: 4.83
Beneish M: −2.54
Dividend safety: 74/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Impairment Feb 4, 2026

All filings →

Insider Decisions trades per month

Total buys 2.31

Total sells 15.06

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	2	—	—	—	—
Sell	1	4	1	2	—	—	—	—	—	1	2	1

Insider Ownership 1.66%

Capital & Financial Ratios $m

Market Cap 65,150.00

Revenue 332,771.32

Net Income 2,639.25

Free Cash Flow 4,105.92

Net Debt 8,907.95

Current Ratio 0.93

Debt/Equity 3.62

P/E ratio 25.20

Fwd P/E 14.50

P/S ratio 0.20

P/B ratio 20.31

Past 5Y EPS Growth —

This Y EPS Growth 11.78%

Next Y EPS Growth 10.47%

Next Y revenue growth 4.89%

Next 5Y EPS Growth 10.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 73.34%

10-year low 10-year high

P/S against its own 10 years 96.24%

10-year low 10-year high

P/B against its own 10 years 52.75%

10-year low 10-year high

EV/Sales against its own 10 years 97.71%

10-year low 10-year high

EV/FCF against its own 10 years 78.67%

10-year low 10-year high

Dividends

Payout Ratio 0.18

Annual Dividend Rate 2.40

Annual Dividend Yield 0.70%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	2.38	0.60 0.60 0.60
2025	2.25	0.55 0.55 0.55 0.60
2024	2.08	0.51 0.51 0.51 0.55
2023	1.97	0.49 0.49 0.49 0.51
2022	1.87	0.46 0.46 0.46 0.49
2021	6.82	0.44 1.23 0.44 1.27 0.44 1.27 0.46 1.27
2020	6.59	0.42 1.22 0.42 1.22 0.42 1.22 0.44 1.23
2019	6.36	0.40 1.10 0.40 1.22 0.40 1.22 0.40 1.22
2018	5.68	0.38 0.98 0.38 1.03 0.38 1.03 0.40 1.10
2017	5.06	0.37 0.80 0.37 0.90 0.37 0.90 0.38 0.98
2016	3.78	0.34 0.53 0.34 0.53 0.34 0.53 0.37 0.80

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2,592	3,133	4,356	2,815
Receivables	20,988	23,872	25,225	25,448
Inventory	17,455	18,999	20,492	21,030
Other	—	—	—	3,836
	42,799	47,718	52,239	55,335

	2023	2024	2025	Q'26
Payables	45,836	50,942	54,720	54,700
ST’ Debt	641	576	118	279
Other	—	—	—	870
	48,831	54,277	57,821	59,197

Compound Annual Growth %

	10y	5y	3y
Sales	8.98%	11.09%	10.43%
Cash Flow	(0.12%)	11.92%	12.76%
Earnings	0.00%	0.00%	(2.92%)
Book Value	10.98%	0.00%	190.49%

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	85,932	78,356	84,755	—	—
’25	81,487	75,454	80,664	83,729	321,333
’24	72,253	68,414	74,241	79,050	293,959
’23	62,847	63,457	66,947	68,922	262,173
’22	59,629	57,719	60,065	61,174	238,587
’21	52,517	49,154	53,406	58,912	213,989
’20	47,865	47,418	45,367	49,245	189,894

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(2,305)	1,339	2,654	—	—
’25	(2,719)	3,351	109	3,133	3,875
’24	885	(878)	2,478	1,000	3,485
’23	710	630	745	1,827	3,911
’22	863	267	409	1,164	2,703
’21	903	(454)	1,208	1,010	2,667
’20	143	853	(88)	1,299	2,207

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(2,381)	1,174	2,430	—	—
’25	(2,825)	3,222	(74)	2,884	3,207
’24	811	(991)	2,360	818	2,998
’23	634	527	641	1,651	3,453
’22	784	137	295	991	2,207
’21	838	(540)	1,086	845	2,228
’20	76	776	(195)	1,217	1,874

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	2.87	8.40	3.94	—	—
’25	2.50	3.68	3.52	(1.75)	7.96
’24	2.98	2.09	2.42	0.02	7.53
’23	2.33	2.13	2.35	1.72	8.53
’22	2.13	2.59	1.92	1.40	8.04
’21	1.81	2.10	1.40	2.08	7.39
’20	0.90	4.64	1.41	(23.74)	(16.65)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	68.38	71.90	69.36	70.55	72.06	94.89	127.94	147.48	204.53	223.92	Analyst estimates 2026–2028 Powerpack
	High	103.40	97.85	106.27	94.75	111.25	135.26	174.63	205.83	253.27	377.54
People
People	Employees	19,000	20,000	21,000	22,000	22,000	42,000	44,000	46,000	46,000	51,000
	Revenue/emp, $m	7.73	7.66	8.00	8.16	8.63	5.09	5.42	5.70	6.39	6.30
Income, $m
Income, $m	Revenue	146,850	153,144	167,940	179,589	189,894	213,989	238,587	262,173	293,959	321,333
	Gross margin, %	2.91	2.97	2.75	2.86	2.73	3.24	3.48	3.42	3.37	3.57
	EBT	1,391	918	1,177	967	(5,294)	2,222	2,183	2,161	2,004	2,258
	EBT margin, %	0.95	0.60	0.70	0.54	(2.79)	1.04	0.91	0.82	0.68	0.70
	Net income	1,428	364	1,616	854	(3,400)	1,545	1,667	1,733	1,519	1,568
	Depreciation	392	432	570	498	770	546	710	981	1,119	1,068
Per share, $
Per share, $	Revenue	692.01	701.29	770.82	854.51	927.29	1,039.19	1,144.46	1,294.61	1,480.88	1,657.89
	Earnings	6.73	1.90	7.61	4.07	(16.65)	7.48	8.15	8.62	7.60	8.02
	Cash flow	14.98	6.89	6.48	11.15	10.78	12.95	12.97	19.31	17.55	19.99
	Capex	(2.19)	(2.14)	(1.51)	(1.47)	(1.63)	(2.13)	(2.38)	(2.26)	(2.45)	(3.45)
	Free cash flow	12.79	4.75	4.97	9.68	9.15	10.82	10.59	17.05	15.10	16.55
	Book value	10.03	9.45	14.00	14.24	(4.10)	2.84	0.34	3.29	3.96	9.01
	Shares, m	212	218	218	210	205	206	208	203	199	194
Valuation, ×
Valuation, ×	P/E	11.90	43.84	12.21	20.23	0.00	15.97	16.63	20.80	29.69	38.97
	P/S	0.12	0.12	0.12	0.10	0.10	0.11	0.12	0.14	0.15	0.19
	P/B	8.05	8.81	6.63	5.78	0.00	42.09	395.84	54.43	56.79	34.67
	EV/Sales	0.13	0.13	0.13	0.10	0.10	0.13	0.13	0.15	0.16	0.20
	EV/FCF	6.95	18.84	20.67	9.05	10.34	12.89	13.83	11.14	15.32	19.92
Cash, $m
Cash, $m	Operating cash flow	3,178	1,504	1,411	2,344	2,207	2,667	2,703	3,911	3,485	3,875
	Capex	(465)	(466)	(328)	(309)	(333)	(438)	(496)	(458)	(487)	(668)
	Free cash flow	2,714	1,038	1,083	2,035	1,874	2,228	2,207	3,453	2,998	3,207
Balance, $m
Balance, $m	Working capital	(2,429)	(2,515)	(1,975)	(1,449)	(797)	(2,556)	(3,888)	(6,032)	(6,559)	(5,581)
	Total debt	4,463	3,794	4,662	4,493	4,120	6,684	5,703	4,787	4,388	7,661
	Net debt	1,721	1,359	2,170	1,119	(478)	4,137	2,315	2,195	1,255	3,305
	Shareholders’ equity	2,129	2,064	3,050	2,993	(840)	584	71	666	787	1,747
Returns, %
Returns, %	ROA	4.64	1.06	4.54	2.23	(8.17)	3.03	2.98	2.93	2.33	2.16
	ROIC	24.77	19.36	17.29	16.90	0.00	31.17	61.99	51.12	66.57	32.52
	ROE	104.01	17.38	64.85	28.31	(316.56)	(1,206.73)	518.18	473.26	207.72	122.67

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MCK McKesson Corporation	$116.4B	26.8×	18.3×	+7.72% (above 0%: growing)	−17.68% (below 0%: shrinking)	+66.40% (above 0%: growing)	3.50%	1.25%	Compare
COR Cencora, Inc.	$65.2B	25.2×	14.5×	+5.07% (above 0%: growing)	+11.27% (above 0%: growing)	+3,385.25% (above 0%: growing)	4.26%	1.32%
CAH Cardinal Health, Inc.	$58.8B	35.0×	23.3×	+5.84% (above 0%: growing)	+68.32% (above 0%: growing)	+10.87% (above 0%: growing)	4.02%	1.14%	Compare
HSIC Henry Schein, Inc.	$9.7B	25.0×	18.5×	+6.73% (above 0%: growing)	+16.90% (above 0%: growing)	+140.91% (above 0%: growing)	31.84%	4.95%	Compare
AHG Akso Health Group Sponsored ADR	$1.2B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%	Compare
FOCL FocalTherics	$154.8M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)	Compare
COSM Cosmos Health Inc.	$33.9M	— (loss-making)	25.1×	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)	Compare
ACH Accendra Health, Inc.	$20.1M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)	Compare
HKPD Cellyan Biotechnology Co., Ltd	$17.1M	—	—	—	—	−90.45% (below 0%: shrinking)	—	—	Compare
Median of peers	$652.4M	26.8×	20.9×	+7.72%	+16.90%	+10.13%	7.96%	0.00%

All 11 Medical Distribution stocks →

Cencora, Inc. (COR) key facts

Strength: Cencora, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $321.3 billion, up 9.31% from fiscal 2024.
Cencora, Inc. (COR) is a Medical Distribution company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, COR traded at $340.66, a market capitalization of $65.2 billion.
Cencora, Inc. pays an annual dividend of $2.40 per share, a yield of 0.70%, with a payout ratio of 17.8%.
Return on equity was 122.7% and debt-to-equity 3.62.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 4.83 (safe zone) for fiscal 2025.